ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
108.08
-0.97 (-0.89%)
As of 11:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close109.05
Open108.72
Bid108.15 x 900
Ask108.17 x 1000
Day's Range107.85 - 108.89
52 Week Range34.53 - 114.20
Volume88,179
Avg. Volume2,002,808
Market Cap4.113B
Beta (3Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)-2.31
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est104.97
Trade prices are not sourced from all markets
  • Markityesterday

    See what the IHS Markit Score report has to say about Spark Therapeutics Inc.

    Spark Therapeutics Inc NASDAQ/NGS:ONCEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for ONCE with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 13. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding ONCE is favorable, with net inflows of $3.74 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GuruFocus.com2 days ago

    Prem Watsa Buys Buffett's Red Hat, Boosts Micron in 1st Quarter

    Investor buys 5 positions for portfolio

  • Adage Capital Management’s Latest Portfolio Moves
    Insider Monkey6 days ago

    Adage Capital Management’s Latest Portfolio Moves

    Adage Capital Management is a Boston-based hedge fund, launched by Phil Gross and Robert Atchinson back in 2001. Both Phil Gross and  Robert Atchinson previously worked at Harvard University’s endowment, and their team managed to beat the S&P 500 Index by an average of 4.5 percentage points annually. Considering this success, it comes as no […]

  • $4.8B Roche-Spark deal delayed, once again
    American City Business Journals8 days ago

    $4.8B Roche-Spark deal delayed, once again

    Roche and Spark Therapeutics are delaying their $4.8 billion deal for a third time to again give federal regulators more time to review the proposed sale of the Philadelphia gene therapy company.

  • Reuters8 days ago

    Roche pushes back Spark takeover again as regulatory review drags on

    Swiss drugmaker Roche is pushing back its $4.3 billion (3.3 billion pounds) takeover offer for gene therapy specialist Spark Therapeutics for a third time in recent months, this time until June 14, as a U.S. regulatory review of the deal drags on. Roche and Spark are now due to refile their premerger notification on May 23, "in order to provide the government with additional time," the companies said in a joint statement on Tuesday. Roche has said the Federal Trade Commission (FTC) needed even more time to complete its review.

  • GlobeNewswire8 days ago

    Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

    OTCQX: RHHBY) and Spark Therapeutics, Inc. (ONCE) ("Spark") today announced that Roche and Spark intend to refile on or about 23 May 2019 their respective Premerger Notification and Report Forms under the Hart-Scott-Rodino Act (the "HSR Act") in connection with Roche`s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated 7 March 2019 (as it may be amended and supplemented from time to time, the "Offer"). Following the refiling by Roche, the waiting period applicable to the pending acquisition will expire at 11:59 p.m., New York City time, on or about 7 June 2019, but this period may be shortened if the government grants "early termination" of the waiting period, or it may change if Roche voluntarily withdraws and Roche refiles its Premerger Notification and Report Forms in order to restart the 15-day waiting period or if the reviewing agency issues a formal request for additional information and documentary material.

  • Will Spark Therapeutics (ONCE) Report Negative Q1 Earnings? What You Should Know
    Zacks15 days ago

    Will Spark Therapeutics (ONCE) Report Negative Q1 Earnings? What You Should Know

    Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Mario Gabelli's Top 7 Buys of the 1st Quarter
    GuruFocus.com19 days ago

    Mario Gabelli's Top 7 Buys of the 1st Quarter

    2019 Value Conference speaker releases portfolio

  • Did Hedge Funds Drop The Ball On Spark Therapeutics Inc (ONCE) ?
    Insider Monkey20 days ago

    Did Hedge Funds Drop The Ball On Spark Therapeutics Inc (ONCE) ?

    As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and their long-term focus allows us to profit from the recent […]

  • Roche extends $4.8B Spark tender offer deadline for second time
    American City Business Journals26 days ago

    Roche extends $4.8B Spark tender offer deadline for second time

    The companies said the extension was needed to give federal regulators more time to review the proposed sale of the Philadelphia gene therapy company.

  • Benzinga26 days ago

    The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...

  • Roche faces further delay in $4.3 billion Spark deal amid FTC review
    Reuters26 days ago

    Roche faces further delay in $4.3 billion Spark deal amid FTC review

    Roche on Friday announced another extension of its $4.3 billion (£3.3 billion) offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer than originally expected. Roche earlier this month had extended its offer until May 2, but said the Federal Trade Commission (FTC) needed even more time to complete its review. "The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process," Roche said.

  • Reuters26 days ago

    Roche faces further delay in $4.3 bln Spark deal amid FTC review

    Roche on Friday announced another extension of its $4.3 billion offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer than originally expected. Roche earlier this month had extended its offer until May 2, but said the Federal Trade Commission (FTC) needed even more time to complete its review. "The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process," Roche said.

  • Reuters26 days ago

    Roche again extends $4.3 blillion offer for Spark amid FTC review

    Roche on Friday announced another extension of the Swiss drugmaker's $4.3 billion offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer than originally expected. Roche earlier this month had extended its offer until May 2, but said the Federal Trade Commission (FTC) needed even more time to complete its review. "The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process," Roche said.

  • GlobeNewswire26 days ago

    Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

    OTCQX: RHHBY) and Spark Therapeutics, Inc. (ONCE) ("Spark") today announced that Roche has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Act (the "HSR Act") in connection with Roche`s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the "Shares") of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 7, 2019 (as it may be amended and supplemented from time to time, the "Offer"). The review of the transaction is ongoing, and the parties are actively working with the government to facilitate that process.  In order to provide the government with additional time to complete its current review, Roche has elected to withdraw and refile the Premerger Notification and Report Form under the HSR Act.

  • Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs
    Zackslast month

    Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

    Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.

  • GlobeNewswirelast month

    Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference

    Spark Therapeutics (ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it will serve as the inaugural sponsor of Believe Limited’s first-ever science fair, which will be hosted at the National Hemophilia Foundation’s 71st Bleeding Disorders Conference, Oct. 3 – 5, 2019, in Anaheim, CA. The Science Fair™ will educate children and adults with hemophilia as well as other attendees about the science behind bleeding disorders in a number of engaging ways.

  • Reuterslast month

    Swiss drugmaker Roche ups outlook as sales growth offsets price hit

    By John Miller ZURICH (Reuters) - Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald ...

  • GlobeNewswirelast month

    Spark Therapeutics (ONCE) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spark Therapeutics, Inc. Concerning Its Proposed Merger With Roche Holdings, Inc. – ONCE

    Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spark Therapeutics, Inc. (“Spark” or the “Company”) (ONCE) in connection with the proposed sale of Spark to Roche Holdings, Inc. (“Roche”). If you are a Spark shareholder and would like to discuss your legal rights and options, please visit Spark (ONCE) Merger or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The lawsuit alleges that Defendants issued a materially misleading proxy statement recommending that Spark shareholders tender their shares to Roche.

  • Ophthotech Gets Rights to Gene Therapy for BEST Disease
    Zackslast month

    Ophthotech Gets Rights to Gene Therapy for BEST Disease

    Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

  • Biotechnology Market on a Tear: 5 ETFs in Spotlight
    Zackslast month

    Biotechnology Market on a Tear: 5 ETFs in Spotlight

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.